Evoxac - (30 mg; Capsule)

Generic Name	Cevimeline Hydrochloride	**Innovator**	Daiichi Sankyo
Dosage	30 mg; Capsule	**Branded US Sales**	Less Than $1000 mn
Probable FTF	Less Than 5	**Known Para IV Filers**	Less Than 5
Other ANDA developers	Less Than 5	**Tentative Approvals**	None
Final Approvals	More Than 5	**Generic Launches**	More Than 5
Indication	indicated for the treatment of symptoms of dry mouth in patients with Sjogren's Syndrome.		
Complexities	Yes		

Chronology Of Events
Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary
Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status
Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition
Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events
Please Contact contact@researchdelta.com to get Detailed Information.

Evoxac - (30MG; CAPSULE)

Generic Name	Cevimeline Hydrochloride	**Innovator**	Cosette
Dosage	30MG; CAPSULE	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	None	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	EVOXAC is a cholinergic agonist indicated for the treatment of symptoms of dry mouth in adults with Sjögren's disease.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.